At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS November 08, 2024Vol.50 No.42By Paul Goldberg
Trials & Tribulations A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment November 08, 2024Vol.50 No.42By Otis W. Brawley
Conversation with The Cancer Letter 2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice November 08, 2024Vol.50 No.42By Jacquelyn Cobb
Arteaga, Bhardwaj, Coussens, Jagsi, Schrag named members of the National Academy of Medicine November 08, 2024Vol.50 No.42By Jacquelyn Cobb
FreeIn the Archives Trump 2016: A look back at the 45th president’s impact on oncology November 08, 2024Vol.50 No.42By Katie Goldberg and Claire Marie Porter
Conversation with The Cancer Letter Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinicsThe state has the second highest (and rising) cancer rates in the U.S. November 01, 2024Vol.50 No.41By Paul Goldberg
Regulatory News At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference November 01, 2024Vol.50 No.41By Claire Marie Porter
Regulatory News FDA extends shelf-life for IV fluids in shortage after Hurricane Helene November 01, 2024Vol.50 No.41By Claire Marie Porter
Trials & Tribulations Addressing high cancer mortality in Native Hawaiian and Pacific Islander populationsA call for equity in cancer research November 01, 2024Vol.50 No.41By Naoto T. Ueno
FreeIn the Archives “Less Radical” podcast: Resistance to change, a data scandal November 01, 2024Vol.50 No.41
